Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
KRKronos Bio, Inc. logo

Kronos Bio, Inc. (KRON)

NASDAQ Global Select · Currency in USD
$0.88 ▲ +0.01 (+1.49%)
At close: Jun 20, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.87
Open
$0.88
Day's Range
$0.87 – $0.88
52 Week Range
$0.65 – $1.46
Volume
53,687
Avg. Volume
855,959
Market Cap
$53.65M
Beta (5Y Monthly)
1.64
PE Ratio (TTM)
--
EPS (TTM)
-$1.43
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$1.63

Profile: Kronos Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
8
CEO
Deborah A. Knobelman

Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity. The company's primary investigational drug, entospletinib (ENTO), is an orally administered, selective inhibitor of spleen tyrosine kinase (SYK), designed for patients with acute myeloid leukemia.

Earnings

DateEst.Actual
May 8, 2025-$0.30-$0.14Beat
Mar 18, 2025-$0.30-$0.43Miss
Nov 13, 2024-$0.26-$0.23Beat
Aug 8, 2024-$0.32-$0.27Beat
May 9, 2024-$0.43-$0.50Miss
Mar 21, 2024-$0.51-$0.43Beat

Analyst view

Consensus price target
$1.63 ▲ +85.2%
Range $1.00 – $2.25
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on KRON and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.